Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jianping Yin

Showing results (131-140 of 139) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 139 results.
Journal of Medicinal Chemistry|March 29, 2021
Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a 5-Fluoro-4-(3<i>H</i>)-quinazolinone Aryl Urea pan-RAF Kinase InhibitorMalcolm P Huestis, Darlene Dela Cruz, Antonio G DiPasquale, et al.
Bioorganic & Medicinal Chemistry Letters|May 13, 2014
Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2James F Blake, John J Gaudino, Jason De Meese, et al.
Nature Communications|February 18, 2021
Genome sequences reveal global dispersal routes and suggest convergent genetic adaptations in seahorse evolutionChunyan Li, Melisa Olave, Yali Hou, et al.
Journal of Medicinal Chemistry|November 11, 2014
Discovery of selective and noncovalent diaminopyrimidine-based inhibitors of epidermal growth factor receptor containing the T790M resistance mutationEmily J Hanan, Charles Eigenbrot, Marian C Bryan, et al.
Journal of Medicinal Chemistry|May 27, 2016
Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical DevelopmentJames F Blake, Michael Burkard, Jocelyn Chan, et al.
Bioorganic & Medicinal Chemistry Letters|July 17, 2019
Design of a brain-penetrant CDK4/6 inhibitor for glioblastomaSarah M Bronner, Karl A Merrick, Jeremy Murray, et al.
Science Translational Medicine|August 5, 2021
TGFβ2 and TGFβ3 isoforms drive fibrotic disease pathogenesisTianhe Sun, Zhiyu Huang, Wei-Ching Liang, et al.
Science Translational Medicine|December 14, 2022
Dual antibody inhibition of KLK5 and KLK7 for Netherton syndrome and atopic dermatitisJoseph Chavarria-Smith, Cecilia P C Chiu, Janet K Jackman, et al.
Nature|May 6, 2021
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanomaIvana Yen, Frances Shanahan, Jeeyun Lee, et al.
Pageof 14

Showing results (131-140 of 139) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 139 results.
Journal of Medicinal Chemistry|March 29, 2021
Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a 5-Fluoro-4-(3<i>H</i>)-quinazolinone Aryl Urea pan-RAF Kinase InhibitorMalcolm P Huestis, Darlene Dela Cruz, Antonio G DiPasquale, et al.
Bioorganic & Medicinal Chemistry Letters|May 13, 2014
Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2James F Blake, John J Gaudino, Jason De Meese, et al.
Nature Communications|February 18, 2021
Genome sequences reveal global dispersal routes and suggest convergent genetic adaptations in seahorse evolutionChunyan Li, Melisa Olave, Yali Hou, et al.
Journal of Medicinal Chemistry|November 11, 2014
Discovery of selective and noncovalent diaminopyrimidine-based inhibitors of epidermal growth factor receptor containing the T790M resistance mutationEmily J Hanan, Charles Eigenbrot, Marian C Bryan, et al.
Journal of Medicinal Chemistry|May 27, 2016
Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical DevelopmentJames F Blake, Michael Burkard, Jocelyn Chan, et al.
Bioorganic & Medicinal Chemistry Letters|July 17, 2019
Design of a brain-penetrant CDK4/6 inhibitor for glioblastomaSarah M Bronner, Karl A Merrick, Jeremy Murray, et al.
Science Translational Medicine|August 5, 2021
TGFβ2 and TGFβ3 isoforms drive fibrotic disease pathogenesisTianhe Sun, Zhiyu Huang, Wei-Ching Liang, et al.
Science Translational Medicine|December 14, 2022
Dual antibody inhibition of KLK5 and KLK7 for Netherton syndrome and atopic dermatitisJoseph Chavarria-Smith, Cecilia P C Chiu, Janet K Jackman, et al.
Nature|May 6, 2021
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanomaIvana Yen, Frances Shanahan, Jeeyun Lee, et al.
Pageof 14